Answers are grounded in this paper and cite their sources.
There is still no standard treatment for non-clear cell renal cell carcinomas. Sunitinib is the most examined drug because of its effectiveness in retrospective studies and clinical trials, and is the preferred first-line drug in the National Comprehensive Cancer Network guideline. Temsirolimus is an option as a first-line drug, especially for poor-risk non-clear cell renal cell carcinoma patients. Everolimus, pazopanib, axitinib and nivolmab might also be viable options. Clinical trials are still required to gather evidence regarding non-clear cell renal cell carcinoma treatment. Because each non-clear cell renal cell carcinoma has a different genetic background and molecular features, specific treatment for each non-clear cell renal cell carcinoma should be established. From the results of a Japanese multicenter study, tyrosine kinase inhibitors might be better used for metastatic papillary renal cell carcinoma in both first- and second-line settings. Both tyrosine kinase inhibitors and mammalian target of rapamicin inhibitors are effective for metastatic chromophobe renal cell carcinoma, but the preferred first-line drug has not been determined. Platinum-based chemotherapies are currently recommended for metastatic collecting duct carcinoma, and anti-angiogenic drugs are effective in some cases. Tyrosine kinase inhibitors, especially sunitinib, appear to be effective for X11.2 translocation renal cell carcinoma among the microphthalmia-associated transcription family of translocation renal cell carcinomas. Evidence is still lacking regarding the treatment for other rare non-clear cell renal cell carcinomas. Appropriate sequential therapies using antivascular endothelial growth factor therapies, mammalian target of rapamicin inhibitors and immuno-oncology drugs should be established for each non-clear cell renal cell carcinoma.
No takes yet. Share an insight, caveat, or question.
Keiichi Ito (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: